The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: A matched-pair analysis

Richard K Valicenti, Leonard G. Gomella, Mohammed Ismail, Steve E. Strup, S. Grant Mulholland, Adam P. Dicker, Robert O. Petersen, Craig J. Newschaffer

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Purpose: This study examines the effect of adjuvant radiation therapy (RT) on outcome in patients with pT3N0 prostate cancer and makes comparisons to a matched control group. Methods and Materials: At our center, 149 patients undergoing radical prostatectomy were found to have pT3N0 prostate cancer, had an undetectable postoperative prostate-specific antigen (PSA) level, and had no immediate hormonal therapy. Fifty-two patients received adjuvant RT within 3 to 6 months of surgery. Ninety-seven underwent radical prostatectomy alone and were observed until PSA failure. From these two cohorts, we matched patients 1:1 according to preoperative PSA (<10 ng/ml vs. >10 ng/ml), Gleason score (<7 vs. ≥7), seminal vesicle invasion, and surgical margin status. Seventy-two patients (36 pairs) were included in the analysis. Median follow-up time was 41 months. We calculated a matched-pairs risk ratio for cumulative risk of PSA relapse (a rise above 0.2 ng/ml). Results: After controlling for the prognostic factors by matching, there was an 88% reduction (95% confidence interval [CI]: 78-93%) in the risk of PSA relapse associated with adjuvant RT. The 5-year freedom from PSA relapse rate was 89% (95% CI: 76-100%) for patients receiving adjuvant RT as compared to 55% (95% CI: 34-79%) for those undergoing radical prostatectomy alone. Conclusions: These data suggest that adjuvant RT for pT3N0 prostate cancer may significantly reduce the risk of PSA failure as compared to radical prostatectomy alone. Its effect on clinical outcome awaits further follow- up.

Original languageEnglish (US)
Pages (from-to)53-58
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume45
Issue number1
DOIs
StatePublished - Aug 1 1999
Externally publishedYes

Fingerprint

Matched-Pair Analysis
antigens
Prostate-Specific Antigen
radiation therapy
Prostatic Neoplasms
Radiotherapy
cancer
Prostatectomy
confidence
Confidence Intervals
intervals
Recurrence
Neoplasm Grading
Seminal Vesicles
surgery
margins
therapy
Research Design
Odds Ratio
Control Groups

Keywords

  • Adjuvant radiation therapy
  • Prostate cancer
  • Prostatectomy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer : A matched-pair analysis. / Valicenti, Richard K; Gomella, Leonard G.; Ismail, Mohammed; Strup, Steve E.; Mulholland, S. Grant; Dicker, Adam P.; Petersen, Robert O.; Newschaffer, Craig J.

In: International Journal of Radiation Oncology Biology Physics, Vol. 45, No. 1, 01.08.1999, p. 53-58.

Research output: Contribution to journalArticle

Valicenti, Richard K ; Gomella, Leonard G. ; Ismail, Mohammed ; Strup, Steve E. ; Mulholland, S. Grant ; Dicker, Adam P. ; Petersen, Robert O. ; Newschaffer, Craig J. / The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer : A matched-pair analysis. In: International Journal of Radiation Oncology Biology Physics. 1999 ; Vol. 45, No. 1. pp. 53-58.
@article{cc77695c2dae47f78021728b1f74cfaa,
title = "The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: A matched-pair analysis",
abstract = "Purpose: This study examines the effect of adjuvant radiation therapy (RT) on outcome in patients with pT3N0 prostate cancer and makes comparisons to a matched control group. Methods and Materials: At our center, 149 patients undergoing radical prostatectomy were found to have pT3N0 prostate cancer, had an undetectable postoperative prostate-specific antigen (PSA) level, and had no immediate hormonal therapy. Fifty-two patients received adjuvant RT within 3 to 6 months of surgery. Ninety-seven underwent radical prostatectomy alone and were observed until PSA failure. From these two cohorts, we matched patients 1:1 according to preoperative PSA (<10 ng/ml vs. >10 ng/ml), Gleason score (<7 vs. ≥7), seminal vesicle invasion, and surgical margin status. Seventy-two patients (36 pairs) were included in the analysis. Median follow-up time was 41 months. We calculated a matched-pairs risk ratio for cumulative risk of PSA relapse (a rise above 0.2 ng/ml). Results: After controlling for the prognostic factors by matching, there was an 88{\%} reduction (95{\%} confidence interval [CI]: 78-93{\%}) in the risk of PSA relapse associated with adjuvant RT. The 5-year freedom from PSA relapse rate was 89{\%} (95{\%} CI: 76-100{\%}) for patients receiving adjuvant RT as compared to 55{\%} (95{\%} CI: 34-79{\%}) for those undergoing radical prostatectomy alone. Conclusions: These data suggest that adjuvant RT for pT3N0 prostate cancer may significantly reduce the risk of PSA failure as compared to radical prostatectomy alone. Its effect on clinical outcome awaits further follow- up.",
keywords = "Adjuvant radiation therapy, Prostate cancer, Prostatectomy",
author = "Valicenti, {Richard K} and Gomella, {Leonard G.} and Mohammed Ismail and Strup, {Steve E.} and Mulholland, {S. Grant} and Dicker, {Adam P.} and Petersen, {Robert O.} and Newschaffer, {Craig J.}",
year = "1999",
month = "8",
day = "1",
doi = "10.1016/S0360-3016(99)00169-8",
language = "English (US)",
volume = "45",
pages = "53--58",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer

T2 - A matched-pair analysis

AU - Valicenti, Richard K

AU - Gomella, Leonard G.

AU - Ismail, Mohammed

AU - Strup, Steve E.

AU - Mulholland, S. Grant

AU - Dicker, Adam P.

AU - Petersen, Robert O.

AU - Newschaffer, Craig J.

PY - 1999/8/1

Y1 - 1999/8/1

N2 - Purpose: This study examines the effect of adjuvant radiation therapy (RT) on outcome in patients with pT3N0 prostate cancer and makes comparisons to a matched control group. Methods and Materials: At our center, 149 patients undergoing radical prostatectomy were found to have pT3N0 prostate cancer, had an undetectable postoperative prostate-specific antigen (PSA) level, and had no immediate hormonal therapy. Fifty-two patients received adjuvant RT within 3 to 6 months of surgery. Ninety-seven underwent radical prostatectomy alone and were observed until PSA failure. From these two cohorts, we matched patients 1:1 according to preoperative PSA (<10 ng/ml vs. >10 ng/ml), Gleason score (<7 vs. ≥7), seminal vesicle invasion, and surgical margin status. Seventy-two patients (36 pairs) were included in the analysis. Median follow-up time was 41 months. We calculated a matched-pairs risk ratio for cumulative risk of PSA relapse (a rise above 0.2 ng/ml). Results: After controlling for the prognostic factors by matching, there was an 88% reduction (95% confidence interval [CI]: 78-93%) in the risk of PSA relapse associated with adjuvant RT. The 5-year freedom from PSA relapse rate was 89% (95% CI: 76-100%) for patients receiving adjuvant RT as compared to 55% (95% CI: 34-79%) for those undergoing radical prostatectomy alone. Conclusions: These data suggest that adjuvant RT for pT3N0 prostate cancer may significantly reduce the risk of PSA failure as compared to radical prostatectomy alone. Its effect on clinical outcome awaits further follow- up.

AB - Purpose: This study examines the effect of adjuvant radiation therapy (RT) on outcome in patients with pT3N0 prostate cancer and makes comparisons to a matched control group. Methods and Materials: At our center, 149 patients undergoing radical prostatectomy were found to have pT3N0 prostate cancer, had an undetectable postoperative prostate-specific antigen (PSA) level, and had no immediate hormonal therapy. Fifty-two patients received adjuvant RT within 3 to 6 months of surgery. Ninety-seven underwent radical prostatectomy alone and were observed until PSA failure. From these two cohorts, we matched patients 1:1 according to preoperative PSA (<10 ng/ml vs. >10 ng/ml), Gleason score (<7 vs. ≥7), seminal vesicle invasion, and surgical margin status. Seventy-two patients (36 pairs) were included in the analysis. Median follow-up time was 41 months. We calculated a matched-pairs risk ratio for cumulative risk of PSA relapse (a rise above 0.2 ng/ml). Results: After controlling for the prognostic factors by matching, there was an 88% reduction (95% confidence interval [CI]: 78-93%) in the risk of PSA relapse associated with adjuvant RT. The 5-year freedom from PSA relapse rate was 89% (95% CI: 76-100%) for patients receiving adjuvant RT as compared to 55% (95% CI: 34-79%) for those undergoing radical prostatectomy alone. Conclusions: These data suggest that adjuvant RT for pT3N0 prostate cancer may significantly reduce the risk of PSA failure as compared to radical prostatectomy alone. Its effect on clinical outcome awaits further follow- up.

KW - Adjuvant radiation therapy

KW - Prostate cancer

KW - Prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=0032807403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032807403&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(99)00169-8

DO - 10.1016/S0360-3016(99)00169-8

M3 - Article

C2 - 10477006

AN - SCOPUS:0032807403

VL - 45

SP - 53

EP - 58

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -